Rôle du peptide vasoactif intestinal (VIP) dans la stéroïdogenèse et le vieillissement testiculaire

Translated title of the contribution: Role of vasoactive intestinal peptide (VIP) in steroidogenesis and aging in mouse testis

Arnaud Lacombe, Vincent Lelievre, Charles Roselli, Jean Marc Muller, James A. Waschek, Eric Vilain

Research output: Contribution to journalArticle

Abstract

VIP (vasoactive intestinal peptide) neuropeptide has long been considered to be putative regulator of testicular functions. In vitro evidence suggests that VIP could play an important role in testosterone biosynthesis. However, the endogenous role of VIP on testicular functions remained to be demonstrated. In C57BL/6 mice exhibiting complete disruption of the VIP gene, the authors observed that male fertility remained intact but serum testosterone levels were lower than those of WT littermates. At the age of 4 months, this phenotype was accompanied by reduced steroidogenesis due to inhibition of the expression of StAR (steroidogenic acute regulatory protein) and 3βHSD (3β-hydroxysteroid dehydrogenase) in the testis. In addition, serum levels of FSH (Follicle-stimulating hormone) but not LH (Luteinizing hormone) were reduced in young KO males. Testicular anatomy also revealed a subtle but significantly higher percentage of degenerated seminiferous tubules in 4-month-old VIP-/- animals compared to WT. In aging animals (15 months old), control males showed typical testicular aging including severe degeneration of seminiferous tubules, a dramatic decrease in serum testosterone levels and a reduction in StAR and 3β-HSD gene expression. In age-matched VIP-/- males, serum levels of testosterone and steroidogenic enzymes were still very low. Interestingly, in contrast with young mice, testicular degeneration at 15 months was significantly less severe marked in VIP-/- mice than in WT mice. Altogether, these results suggest that: 1) VIP is an important factor for regulating testosterone biosynthesis and FSH secretion and 2) VIP regulates testicular aging.

Original languageFrench
Pages (from-to)123-128
Number of pages6
JournalAndrologie
Volume17
Issue number2
StatePublished - Jun 2007

Fingerprint

Vasoactive Intestinal Peptide
Testis
Testosterone
Seminiferous Tubules
Follicle Stimulating Hormone
Serum
3-Hydroxysteroid Dehydrogenases
Luteinizing Hormone
Neuropeptides
Inbred C57BL Mouse
Fertility
Anatomy
Phenotype
Gene Expression
Enzymes

Keywords

  • Follicle-stimulating hormone
  • Luteinizing hormone
  • Neuropeptide
  • Testicular aging
  • Testosterone biosynthesis

ASJC Scopus subject areas

  • Urology
  • Endocrinology

Cite this

Lacombe, A., Lelievre, V., Roselli, C., Muller, J. M., Waschek, J. A., & Vilain, E. (2007). Rôle du peptide vasoactif intestinal (VIP) dans la stéroïdogenèse et le vieillissement testiculaire. Andrologie, 17(2), 123-128.

Rôle du peptide vasoactif intestinal (VIP) dans la stéroïdogenèse et le vieillissement testiculaire. / Lacombe, Arnaud; Lelievre, Vincent; Roselli, Charles; Muller, Jean Marc; Waschek, James A.; Vilain, Eric.

In: Andrologie, Vol. 17, No. 2, 06.2007, p. 123-128.

Research output: Contribution to journalArticle

Lacombe, A, Lelievre, V, Roselli, C, Muller, JM, Waschek, JA & Vilain, E 2007, 'Rôle du peptide vasoactif intestinal (VIP) dans la stéroïdogenèse et le vieillissement testiculaire', Andrologie, vol. 17, no. 2, pp. 123-128.
Lacombe A, Lelievre V, Roselli C, Muller JM, Waschek JA, Vilain E. Rôle du peptide vasoactif intestinal (VIP) dans la stéroïdogenèse et le vieillissement testiculaire. Andrologie. 2007 Jun;17(2):123-128.
Lacombe, Arnaud ; Lelievre, Vincent ; Roselli, Charles ; Muller, Jean Marc ; Waschek, James A. ; Vilain, Eric. / Rôle du peptide vasoactif intestinal (VIP) dans la stéroïdogenèse et le vieillissement testiculaire. In: Andrologie. 2007 ; Vol. 17, No. 2. pp. 123-128.
@article{657e2296237c40b68017b1e13ac2e2e7,
title = "R{\^o}le du peptide vasoactif intestinal (VIP) dans la st{\'e}ro{\"i}dogen{\`e}se et le vieillissement testiculaire",
abstract = "VIP (vasoactive intestinal peptide) neuropeptide has long been considered to be putative regulator of testicular functions. In vitro evidence suggests that VIP could play an important role in testosterone biosynthesis. However, the endogenous role of VIP on testicular functions remained to be demonstrated. In C57BL/6 mice exhibiting complete disruption of the VIP gene, the authors observed that male fertility remained intact but serum testosterone levels were lower than those of WT littermates. At the age of 4 months, this phenotype was accompanied by reduced steroidogenesis due to inhibition of the expression of StAR (steroidogenic acute regulatory protein) and 3βHSD (3β-hydroxysteroid dehydrogenase) in the testis. In addition, serum levels of FSH (Follicle-stimulating hormone) but not LH (Luteinizing hormone) were reduced in young KO males. Testicular anatomy also revealed a subtle but significantly higher percentage of degenerated seminiferous tubules in 4-month-old VIP-/- animals compared to WT. In aging animals (15 months old), control males showed typical testicular aging including severe degeneration of seminiferous tubules, a dramatic decrease in serum testosterone levels and a reduction in StAR and 3β-HSD gene expression. In age-matched VIP-/- males, serum levels of testosterone and steroidogenic enzymes were still very low. Interestingly, in contrast with young mice, testicular degeneration at 15 months was significantly less severe marked in VIP-/- mice than in WT mice. Altogether, these results suggest that: 1) VIP is an important factor for regulating testosterone biosynthesis and FSH secretion and 2) VIP regulates testicular aging.",
keywords = "Follicle-stimulating hormone, Luteinizing hormone, Neuropeptide, Testicular aging, Testosterone biosynthesis",
author = "Arnaud Lacombe and Vincent Lelievre and Charles Roselli and Muller, {Jean Marc} and Waschek, {James A.} and Eric Vilain",
year = "2007",
month = "6",
language = "French",
volume = "17",
pages = "123--128",
journal = "Basic and Clinical Andrology",
issn = "1166-2654",
publisher = "Springer Science + Business Media",
number = "2",

}

TY - JOUR

T1 - Rôle du peptide vasoactif intestinal (VIP) dans la stéroïdogenèse et le vieillissement testiculaire

AU - Lacombe, Arnaud

AU - Lelievre, Vincent

AU - Roselli, Charles

AU - Muller, Jean Marc

AU - Waschek, James A.

AU - Vilain, Eric

PY - 2007/6

Y1 - 2007/6

N2 - VIP (vasoactive intestinal peptide) neuropeptide has long been considered to be putative regulator of testicular functions. In vitro evidence suggests that VIP could play an important role in testosterone biosynthesis. However, the endogenous role of VIP on testicular functions remained to be demonstrated. In C57BL/6 mice exhibiting complete disruption of the VIP gene, the authors observed that male fertility remained intact but serum testosterone levels were lower than those of WT littermates. At the age of 4 months, this phenotype was accompanied by reduced steroidogenesis due to inhibition of the expression of StAR (steroidogenic acute regulatory protein) and 3βHSD (3β-hydroxysteroid dehydrogenase) in the testis. In addition, serum levels of FSH (Follicle-stimulating hormone) but not LH (Luteinizing hormone) were reduced in young KO males. Testicular anatomy also revealed a subtle but significantly higher percentage of degenerated seminiferous tubules in 4-month-old VIP-/- animals compared to WT. In aging animals (15 months old), control males showed typical testicular aging including severe degeneration of seminiferous tubules, a dramatic decrease in serum testosterone levels and a reduction in StAR and 3β-HSD gene expression. In age-matched VIP-/- males, serum levels of testosterone and steroidogenic enzymes were still very low. Interestingly, in contrast with young mice, testicular degeneration at 15 months was significantly less severe marked in VIP-/- mice than in WT mice. Altogether, these results suggest that: 1) VIP is an important factor for regulating testosterone biosynthesis and FSH secretion and 2) VIP regulates testicular aging.

AB - VIP (vasoactive intestinal peptide) neuropeptide has long been considered to be putative regulator of testicular functions. In vitro evidence suggests that VIP could play an important role in testosterone biosynthesis. However, the endogenous role of VIP on testicular functions remained to be demonstrated. In C57BL/6 mice exhibiting complete disruption of the VIP gene, the authors observed that male fertility remained intact but serum testosterone levels were lower than those of WT littermates. At the age of 4 months, this phenotype was accompanied by reduced steroidogenesis due to inhibition of the expression of StAR (steroidogenic acute regulatory protein) and 3βHSD (3β-hydroxysteroid dehydrogenase) in the testis. In addition, serum levels of FSH (Follicle-stimulating hormone) but not LH (Luteinizing hormone) were reduced in young KO males. Testicular anatomy also revealed a subtle but significantly higher percentage of degenerated seminiferous tubules in 4-month-old VIP-/- animals compared to WT. In aging animals (15 months old), control males showed typical testicular aging including severe degeneration of seminiferous tubules, a dramatic decrease in serum testosterone levels and a reduction in StAR and 3β-HSD gene expression. In age-matched VIP-/- males, serum levels of testosterone and steroidogenic enzymes were still very low. Interestingly, in contrast with young mice, testicular degeneration at 15 months was significantly less severe marked in VIP-/- mice than in WT mice. Altogether, these results suggest that: 1) VIP is an important factor for regulating testosterone biosynthesis and FSH secretion and 2) VIP regulates testicular aging.

KW - Follicle-stimulating hormone

KW - Luteinizing hormone

KW - Neuropeptide

KW - Testicular aging

KW - Testosterone biosynthesis

UR - http://www.scopus.com/inward/record.url?scp=34447558437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34447558437&partnerID=8YFLogxK

M3 - Article

VL - 17

SP - 123

EP - 128

JO - Basic and Clinical Andrology

JF - Basic and Clinical Andrology

SN - 1166-2654

IS - 2

ER -